Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317388048> ?p ?o ?g. }
- W4317388048 endingPage "1155" @default.
- W4317388048 startingPage "1138" @default.
- W4317388048 abstract "Hydrophobic ion pairing (HIP) can successfully increase the drug loading and control the release kinetics of ionizable hydrophilic drugs, addressing challenges that prevent these molecules from reaching the clinic. Nevertheless, polymeric nanoparticle (PNP) formulation development requires trial-and-error experimentation to meet the target product profile, which is laborious and costly. Herein, we design a preformulation framework (solid-state screening, computational approach, and solubility in PNP-forming emulsion) to understand counterion-drug-polymer interactions and accelerate the PNP formulation development for HIP systems. The HIP interactions between a small hydrophilic molecule, AZD2811, and counterions with different molecular structures were investigated. Cyclic counterions formed amorphous ion pairs with AZD2811; the 0.7 pamoic acid/1.0 AZD2811 complex had the highest glass transition temperature (Tg; 162 °C) and the greatest drug loading (22%) and remained as phase-separated amorphous nanosized domains inside the polymer matrix. Palmitic acid (linear counterion) showed negligible interactions with AZD2811 (crystalline-free drug/counterion forms), leading to a significantly lower drug loading despite having similar log P and pKa with pamoic acid. Computational calculations illustrated that cyclic counterions interact more strongly with AZD2811 than linear counterions through dispersive interactions (offset π-π interactions). Solubility data indicated that the pamoic acid/AZD2811 complex has a lower organic phase solubility than AZD2811-free base; hence, it may be expected to precipitate more rapidly in the nanodroplets, thus increasing drug loading. Our work provides a generalizable preformulation framework, complementing traditional performance-indicating parameters, to identify optimal counterions rapidly and accelerate the development of hydrophilic drug PNP formulations while achieving high drug loading without laborious trial-and-error experimentation." @default.
- W4317388048 created "2023-01-19" @default.
- W4317388048 creator A5003999476 @default.
- W4317388048 creator A5009953449 @default.
- W4317388048 creator A5021065018 @default.
- W4317388048 creator A5023482770 @default.
- W4317388048 creator A5031785636 @default.
- W4317388048 creator A5048811821 @default.
- W4317388048 creator A5048851531 @default.
- W4317388048 creator A5051406636 @default.
- W4317388048 creator A5052830864 @default.
- W4317388048 creator A5055421370 @default.
- W4317388048 creator A5065514740 @default.
- W4317388048 creator A5067361587 @default.
- W4317388048 creator A5075117837 @default.
- W4317388048 creator A5079163861 @default.
- W4317388048 creator A5080885145 @default.
- W4317388048 creator A5087855628 @default.
- W4317388048 creator A5090835640 @default.
- W4317388048 date "2023-01-19" @default.
- W4317388048 modified "2023-10-06" @default.
- W4317388048 title "Selecting Counterions to Improve Ionized Hydrophilic Drug Encapsulation in Polymeric Nanoparticles" @default.
- W4317388048 cites W1580991720 @default.
- W4317388048 cites W1892226266 @default.
- W4317388048 cites W1953531402 @default.
- W4317388048 cites W1963542141 @default.
- W4317388048 cites W1972974331 @default.
- W4317388048 cites W1977718318 @default.
- W4317388048 cites W1986147969 @default.
- W4317388048 cites W2013470095 @default.
- W4317388048 cites W2015733115 @default.
- W4317388048 cites W2023978377 @default.
- W4317388048 cites W2024468836 @default.
- W4317388048 cites W2024934556 @default.
- W4317388048 cites W2040432233 @default.
- W4317388048 cites W2040492082 @default.
- W4317388048 cites W2045300362 @default.
- W4317388048 cites W2047925052 @default.
- W4317388048 cites W2055423300 @default.
- W4317388048 cites W2056552133 @default.
- W4317388048 cites W2060679680 @default.
- W4317388048 cites W2061409206 @default.
- W4317388048 cites W2071423096 @default.
- W4317388048 cites W2075179133 @default.
- W4317388048 cites W2078627456 @default.
- W4317388048 cites W2083557320 @default.
- W4317388048 cites W2100719274 @default.
- W4317388048 cites W2112430792 @default.
- W4317388048 cites W2129507043 @default.
- W4317388048 cites W2135486162 @default.
- W4317388048 cites W2146798438 @default.
- W4317388048 cites W2151823004 @default.
- W4317388048 cites W2182301132 @default.
- W4317388048 cites W2309694234 @default.
- W4317388048 cites W2322445506 @default.
- W4317388048 cites W2341037501 @default.
- W4317388048 cites W2415646540 @default.
- W4317388048 cites W2466300182 @default.
- W4317388048 cites W2467820315 @default.
- W4317388048 cites W2531621699 @default.
- W4317388048 cites W2608960821 @default.
- W4317388048 cites W2765953043 @default.
- W4317388048 cites W2772253469 @default.
- W4317388048 cites W2791815761 @default.
- W4317388048 cites W2792097049 @default.
- W4317388048 cites W2884120860 @default.
- W4317388048 cites W2885456953 @default.
- W4317388048 cites W2888608684 @default.
- W4317388048 cites W2908702646 @default.
- W4317388048 cites W2944523005 @default.
- W4317388048 cites W2945182945 @default.
- W4317388048 cites W2969822417 @default.
- W4317388048 cites W2978421255 @default.
- W4317388048 cites W3009906101 @default.
- W4317388048 cites W3018425805 @default.
- W4317388048 cites W3022688382 @default.
- W4317388048 cites W3037075760 @default.
- W4317388048 cites W3134400884 @default.
- W4317388048 cites W3160596090 @default.
- W4317388048 cites W3173228391 @default.
- W4317388048 cites W4223477713 @default.
- W4317388048 doi "https://doi.org/10.1021/acs.molpharmaceut.2c00855" @default.
- W4317388048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36653946" @default.
- W4317388048 hasPublicationYear "2023" @default.
- W4317388048 type Work @default.
- W4317388048 citedByCount "2" @default.
- W4317388048 countsByYear W43173880482023 @default.
- W4317388048 crossrefType "journal-article" @default.
- W4317388048 hasAuthorship W4317388048A5003999476 @default.
- W4317388048 hasAuthorship W4317388048A5009953449 @default.
- W4317388048 hasAuthorship W4317388048A5021065018 @default.
- W4317388048 hasAuthorship W4317388048A5023482770 @default.
- W4317388048 hasAuthorship W4317388048A5031785636 @default.
- W4317388048 hasAuthorship W4317388048A5048811821 @default.
- W4317388048 hasAuthorship W4317388048A5048851531 @default.
- W4317388048 hasAuthorship W4317388048A5051406636 @default.
- W4317388048 hasAuthorship W4317388048A5052830864 @default.
- W4317388048 hasAuthorship W4317388048A5055421370 @default.